Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Aggressive Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Indolent Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Waldenstrom MacroglobulinemiaInterventions:   Procedure: Total-Body Irradiation;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Drug: Cyclosporine;   Procedure: Peripheral Blood Stem Cell TransplantationSponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)Active, not recruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials